RxDoctor Payments Data

Gawu Kamara Bankole, MD

Family Medicine · Royersford, PANPI 1679836183

Payments from drug & device makers

$13,291in general payments, 2019–2025

Across 780 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Pfizer$773
  • Abbott$598
  • plus $6K from 48 others

What the payments were for

  • Food & beverage$13,265100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,291 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$131,891
Medicare patients
300
Services billed
1,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$34,896
MounjaroTirzepatide34$34,637
EliquisApixaban26$29,486
OzempicSemaglutide32$29,297
FarxigaDapagliflozin Propanediol12$18,825
VraylarCariprazine Hcl11$15,658
Tresiba Flextouch U-100Insulin Degludec23$15,069
BelsomraSuvorexant18$8,647
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,101
Atorvastatin Calcium278$3,509
Levothyroxine Sodium193$2,992
Esomeprazole Magnesium17$2,685
Rosuvastatin Calcium138$2,276
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,208
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$582$34,89624 claims
Lilly USA, LLCMounjaro$1,379$34,63734 claims
PfizerEliquis$773$29,48626 claims
Novo NordiskOzempic$1,860$29,29732 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,257$26,92623 claims
AbbVieVraylar, Synthroid$1,455$16,59127 claims
MerckBelsomra$532$8,64718 claims
Almatica Pharma LLCSertraline Hcl$22$70364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Royersford

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →